Actualités sur Medizinische Behandlung
- plus
CHIESI GROUP CONTINUES GROWTH
Parma, Italy (ots/PRNewswire) - - 2021 Turnover €2.42bn - up 8.6% - Internationally China up 22%, US up >10% - Continued focus on innovation: almost 20% of turnover invested in R&D - Chiesi recognised as Top Employer in eight markets and as Top Employer Europe for 10th consecutive year Growth continues at Chiesi, the international research-focussed pharmaceutical group and its 30 global affiliates with turnover at €2.42bn, up 8.6% vs 2020. Gross operating profit (EBITDA) ...
plusVIVOSENSE ANNOUNCES CLOSING OF $25M SERIES A FINANCING
Newport Beach (ots) - Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor ...
plusFDA approves CartiHeal's Implant for the Treatment of Cartilage and Osteochondral Defects
Kfar Saba, Israel (ots/PRNewswire) - Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint CartiHeal Ltd, developer of implants for the treatment of cartilage and ...
plusGrünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis
Aachen, Germany, and Raleigh, North Carolina (ots) - Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (RTX). The investigational medicine is being developed with the aim of providing patients ...
plusMoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint
Zug, Switzerland (ots/PRNewswire) - - This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical response level of HiSCR75 as the primary endpoint - Expected to enroll over 200 patients with moderate-to-severe HS to ...
plusDTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growth
Boston, Reykjavik, Iceland and Berlin (ots/PRNewswire) - - UnitedHealth Group and Anthem veteran Pamela Stahl joins as Chief Commercial Officer (CCO) and President, North America to lead Sidekick's global commercial strategy, driving revenue growth with international pharmaceutical majors and U.S.-based payers. - Mitchell Mudra joins Sidekick from UnitedHealth Group as ...
plusNanoPass's intradermal injection platform proven to sustain COVID-19 vaccine antibodies using 1/15 of the dose reports Chinese Institute of Medical Biology
Nes Ziona, Israel and Shanghai, China (ots/PRNewswire) - Intradermal COVID vaccination studies are emerging in a global effort to multiply available doses by harnessing skin immunity to reduce dosage required for effective vaccination. In a hallmark study published recently by IMB scientists[1], subjects were ...
plusPioneering research for non-invasive detection of cancer
Vienna / Baar (ots) - Scientists from the Swiss-Austrian research group HealthBiocare GmbH and System Biologie AG, in collaboration with the University of Vienna, have found a new non-invasive approach for the detection of the nine most common types of cancer. Although cancer is a leading cause of death worldwide, there are still no clinically approved tests for broader cancer screening of the population. The earlier ...
plusDEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA
Lausanne, Switzerland and Durban, South Africa (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar® (Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate ...
plusAccord's SONDELBAY ®▼ (teriparatide) is given Green Light by CHMP
Harrow, England (ots/PRNewswire) - Sondelbay – is a self-administered, once-a-day subcutaneous injection for patients with osteoporosis using a pen device - Accord's fourth biosimilar, joins the company's established portfolio across Europe, and marks its first branded product in a new Bone Health franchise representing another great milestone in Accord's growing ...
plusNanoPass's intradermal delivery platform used in Emergex's next generation COVID-19 vaccination study
Nes Ziona, Israel (ots/PRNewswire) - Intradermal COVID-19 vaccination studies are emerging in a global effort to use available doses more effectively by harnessing skin immunity to reduce the dosage required for effective vaccination, as well as to improve the immunogenicity of weaker vaccines. Additionally, there ...
plusHearing loss company Acousia Therapeutics to present data for ACOU085 at ARO 2022 MidWinter Meeting February 5–9
Tübingen (ots) - Acousia Therapeutics GmbH – along with its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen) and Synovo GmbH (Tübingen) – will be presenting data on the the company’s ...
plusALDER HEY AND NEEDLESMART PARTNERSHIP AIMS TO REDUCE 100,000 NEEDLESTICK INJURIES TO NHS HEALTHCARE WORKERS
plusDALI Medical's SAN®Light Passive Safety Needle coupled with a novel Drug Product, Enabling User-friendly Administration
Tel Aviv, Israel (ots/PRNewswire) - DALI Medical Devices, an innovative developer and distributor of drug delivery devices, today announced the first commercial implementation of its SAN-Light passive safety needle. SAN-Light was chosen to be used with ADVANZ PHARMA's MYTOLAC®/MYRELEZ® - the first generic ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Animal experiments and 3R: mucous membrane as a model
Bern (ots) - In an SNSF-funded project, researchers are studying how bacteria infect the lungs. They are developing an alternative to animal testing that complements existing methods. When bacteria enter our lungs or live in our guts, they physically interact with our own cells that line the openings of our body like a protective layer. Some bacteria help us digest, others make us sick. Alexandre Persat from EPF Lausanne ...
plusDEBIOPHARM IINVESTS IN VERISIM LIFE’S $15M SERIES A ROUND TO ADVANCE AI-ENABLED DRUG RESEARCH
Lausanne, Switzerland - San Francisco (ots) - Funding to support BIOiSIMTM computational platform to reduce the need for animal testing by selecting compounds showing promise to cure a disease prior to research in humans Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today their co-investment in California-based start-up VeriSIM Life’s ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Animal experiments and 3R: Wound healing in mice and cell cultures
Bern (ots) - Research projects involving animal experiments employ a variety of methods. An SNSF-funded project on skin diseases, ulcers and cancer exemplifies this. Sabine Werner, professor of cell biology at ETH Zurich, studies how wounds heal. Knowledge of cell and tissue processes helps to better understand, diagnose and treat certain skin diseases. Here the focus is not primarily cuts and abrasions but rather wounds ...
plusNovaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL (ESSENCE-2) of CyclASol® in Dry Eye Disease
Heidelberg, Germany and Cambridge, Mass (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug ...
plusDEBIOPHARM FURTHER EXPLORES THE POTENTIAL OF ITS POTENT, HIGHLY SELECTIVE WEE1 INHIBITOR DEBIO 0123 IN PHASE 1 CANCER STUDY
Lausanne, Switzerland (ots) - Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly ...
plusPHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE'S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS
Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the ...
plusBenevolentAI achieves second major collaboration milestone with novel idiopathic pulmonary fibrosis target selected for AstraZeneca's portfolio
London (ots/PRNewswire) - - Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI's AI-drug discovery platform and experimentally validated by AstraZeneca - Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to ...
plusMenarini Silicon Biosystems Announces Study Results Presented at American Society of Hematology (ASH) Annual Meeting
Bologna, Italy and Huntingdon Valley, Pa. (ots/PRNewswire) - Menarini Silicon Biosystems Announces Study Results Presented at American Society of Hematology (ASH) Annual Meeting Highlighting CELLSEARCH® CMMC assay, a Non-Invasive Liquid Biopsy for the Quantification and Molecular Characterization of Circulating ...
plusNew HARMONY Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL) Research Results from HARMONY to facilitate tailored treatment choices in subtypes of blood cancer
The Hague, The Netherlands (ots/PRNewswire) - - Big Data analyses have produced novel insights that may improve the prognostication of patients with AML and CLL - These results may be used to identify high-risk patients and to make better-informed treatment choices in the future - The new data is presented at the ...
plusThe Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma
Copenhagen, Denmark (ots/PRNewswire) - - Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have been published in The Lancet Regional Health - Europe - REACT demonstrated the real-world effectiveness of allergy immunotherapy (AIT) - including ALK products - in allergic ...
plusFDI World Dental Federation: Prescribing of dental antibiotics up 22% in England during first year of COVID-19 / Prescriptions of all other antibiotics fell during the same period
plusGenomics England; Queen Mary University of London (QMUL)
Whole genome sequencing improves diagnosis of rare diseases and shortens diagnostic journeys for patients, according to world first study
London (ots/PRNewswire) - NB: SCIENCE MEDIA BRIEFING TAKING PLACE 14:00 GMT 9TH NOVEMBER 2021 - whole genome sequencing proved to be a better way to diagnose rare diseases than usual genomic testing methods - whole genome sequencing led to new rare disease diagnoses for NHS patients in some cases ending decades-long ...
plusEPI Health and MC2 Therapeutics Announce Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) now covered on Express Scripts National Preferred Formulary
Charleston, S.c. and Copenhagen, Denmark (ots/PRNewswire) - Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older. EPI Health, LLC, a specialty pharmaceutical company committed to delivering innovative ...
plusWegovy(TM) Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity
Bagsværd, Denmark (ots/PRNewswire) - - The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy(TM) at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo - The trial also showed that 77.1% of study participants who received Wegovy(TM) lost at ...
plusSchweizerischer Nationalfonds / Fonds national suisse
The ethical dilemma of forensic therapy
Bern (ots) - Therapy and reporting to the judiciary - psychiatric professionals in prison have a conflict of loyalties. How do they deal with it? The treatment of people for whom a therapeutic measure has been ordered by the court creates a conflict of loyalties for medical professionals. A study(*) supported by the SNSF reveals how they deal with this in practice. Approximately one thousand people in Switzerland are ...
plus